489 related articles for article (PubMed ID: 38697854)
1. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future.
Wang W; Albadari N; Du Y; Fowler JF; Sang HT; Xian W; McKeon F; Li W; Zhou J; Zhang R
Pharmacol Rev; 2024 May; 76(3):414-453. PubMed ID: 38697854
[TBL] [Abstract][Full Text] [Related]
2. Targeting MDM2-p53 interaction for cancer therapy: are we there yet?
Nag S; Zhang X; Srivenugopal KS; Wang MH; Wang W; Zhang R
Curr Med Chem; 2014; 21(5):553-74. PubMed ID: 24180275
[TBL] [Abstract][Full Text] [Related]
3. An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy.
Li H; Cai X; Yang X; Zhang X
Eur J Med Chem; 2024 Jun; 272():116506. PubMed ID: 38761584
[TBL] [Abstract][Full Text] [Related]
4. MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present).
Rusiecki R; Witkowski J; Jaszczewska-Adamczak J
Recent Pat Anticancer Drug Discov; 2019; 14(4):324-369. PubMed ID: 31642413
[TBL] [Abstract][Full Text] [Related]
5. Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy.
Wang W; Zafar A; Rajaei M; Zhang R
Cells; 2020 May; 9(5):. PubMed ID: 32397368
[TBL] [Abstract][Full Text] [Related]
6. MDM2 inhibition: an important step forward in cancer therapy.
Konopleva M; Martinelli G; Daver N; Papayannidis C; Wei A; Higgins B; Ott M; Mascarenhas J; Andreeff M
Leukemia; 2020 Nov; 34(11):2858-2874. PubMed ID: 32651541
[TBL] [Abstract][Full Text] [Related]
7. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
Haronikova L; Bonczek O; Zatloukalova P; Kokas-Zavadil F; Kucerikova M; Coates PJ; Fahraeus R; Vojtesek B
Cell Mol Biol Lett; 2021 Dec; 26(1):53. PubMed ID: 34911439
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update.
Millard M; Pathania D; Grande F; Xu S; Neamati N
Curr Pharm Des; 2011; 17(6):536-59. PubMed ID: 21391905
[TBL] [Abstract][Full Text] [Related]
9. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
[TBL] [Abstract][Full Text] [Related]
10. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
11. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).
Zak K; Pecak A; Rys B; Wladyka B; Dömling A; Weber L; Holak TA; Dubin G
Expert Opin Ther Pat; 2013 Apr; 23(4):425-48. PubMed ID: 23374098
[TBL] [Abstract][Full Text] [Related]
12. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
Weber L
Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
[TBL] [Abstract][Full Text] [Related]
13. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
14. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
15. Resistance acquisition to MDM2 inhibitors.
Cinatl J; Speidel D; Hardcastle I; Michaelis M
Biochem Soc Trans; 2014 Aug; 42(4):752-7. PubMed ID: 25109953
[TBL] [Abstract][Full Text] [Related]
16. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
17. Natural product MDM2 inhibitors: anticancer activity and mechanisms of action.
Qin JJ; Nag S; Voruganti S; Wang W; Zhang R
Curr Med Chem; 2012; 19(33):5705-25. PubMed ID: 22830335
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
Di J; Zhang Y; Zheng J
Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
Li Q; Lozano G
Clin Cancer Res; 2013 Jan; 19(1):34-41. PubMed ID: 23262034
[TBL] [Abstract][Full Text] [Related]
20. Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.
Zafar A; Wang W; Liu G; Xian W; McKeon F; Zhou J; Zhang R
Cancer Lett; 2021 Jan; 496():16-29. PubMed ID: 33007410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
